<SEC-DOCUMENT>0000313143-18-000060.txt : 20181219
<SEC-HEADER>0000313143-18-000060.hdr.sgml : 20181219
<ACCEPTANCE-DATETIME>20181219083910
ACCESSION NUMBER:		0000313143-18-000060
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181219
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181219
DATE AS OF CHANGE:		20181219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HAEMONETICS CORP
		CENTRAL INDEX KEY:			0000313143
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				042882273
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14041
		FILM NUMBER:		181242269

	BUSINESS ADDRESS:	
		STREET 1:		400 WOOD RD
		CITY:			BRAINTREE
		STATE:			MA
		ZIP:			02184
		BUSINESS PHONE:		7818487100

	MAIL ADDRESS:	
		STREET 1:		400 WOOD ROAD
		CITY:			BRAINTREE
		STATE:			MA
		ZIP:			02184
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-kitems101203and901.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sb4235aa8b91f490888415f9d6a4bf114"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM&#160;8-K</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 OR 15(d)&#160;of The Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date of Report (Date of earliest event reported): </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">December 18, 2018</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">HAEMONETICS CORPORATION</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Massachusetts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-14041</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">04-2882273</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.6640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56%;"></td><td style="width:2%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">400 Wood Road, Braintree, MA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">02184</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">781-848-7100</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former name or former address, if changed since last report.)</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#231f20;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#231f20;">Emerging Growth Company </font><font style="font-family:Wingdings;font-size:11pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:11pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="se468ac4610814eb58f09c629a9b0a7d2"></a></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 1.01  Entry into a Material Definitive Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On December 18, 2018, Haemonetics Corporation (the &#8220;Company&#8221;) entered into an office lease agreement (the &#8220;Lease&#8221;) with OPG 125 Summer Owner (DE) LLC (&#8220;Landlord&#8221;) for 62,066 rentable square feet of space located at 125 Summer Street, Boston, MA (the &#8220;Premises&#8221;).  The Premises will serve as the Company&#8217;s new corporate headquarters and replace its existing location in Braintree, MA.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The term of the Lease is 152 months (including an initial 8 month free-rent period beginning on October 1, 2019) and will commence on the date that Landlord has substantially completed construction of the Premises&#8217; warm shell and all tenant improvements, which is currently targeted as October 1, 2019.  The Company has options to extend the initial term of the Lease for two additional five-year periods.  Landlord has agreed to provide a tenant improvement allowance towards leasehold improvements, and the Company will be responsible for the cost of tenant improvements that exceed such allowance. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In addition to base rent, the Company will be responsible for certain operating expenses specified in the Lease, including a proportionate share of real estate taxes and other customary costs incurred by Landlord.  The Lease also contains customary default provisions allowing the Landlord to terminate the Lease if the Company fails to cure certain breaches of its obligations under the Lease within a specified period of time. In addition, the Company will be obligated to indemnify the Landlord for certain losses incurred in connection with the Company's use and occupancy of the Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The foregoing description of the Lease does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease, a copy of which will be filed with the Company's Quarterly Report on Form 10-Q for the quarterly period ending December 29, 2018.  A copy of the Company&#8217;s press release announcing its entry into the Lease and headquarters relocation to Boston is filed as Exhibit 99.1 to this Current Report on Form 8-K.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 2.03  Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The information set forth under Item 1.01 is hereby incorporated by reference into this Item 2.03.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 9.01  Financial Statements and Exhibits.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(d</font><font style="font-family:inherit;font-size:11pt;">)  Exhibits</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:7%;"></td><td style="width:83%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a991pressreleaseofficelease.htm"><font style="font-family:inherit;font-size:11pt;">99.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Press release dated December 19, 2018</font></div></td></tr></table></div></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sb61beea22342403c8526db93e43f5022"></a></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SIGNATURES</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:27%;"></td><td style="width:6%;"></td><td style="width:7%;"></td><td style="width:32%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">HAEMONETICS CORPORATION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: December 19, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Christopher Simon</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Christopher Simon</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a991pressreleaseofficelease.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB3AC53C06A2B332AC4E8C39BE3AFE3B3"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:left;"><img src="haemo.jpg" alt="haemo.jpg" style="height:53px;width:189px;"></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">FOR IMMEDIATE RELEASE&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:46%;"></td><td style="width:4%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Investor Contact:</font></div><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Gerry Gould, VP-Investor Relations</font></div><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">(781) 356-9402</font></div><div style="font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#"><font style="font-family:Arial;font-size:11pt;">gerry.gould@haemonetics.co</font></a><font style="font-family:Arial;font-size:11pt;color:#0000ff;text-decoration:underline;">m</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Media Contact:</font></div><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Carla Burigatto, VP-Communications</font></div><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">(781) 348-7263</font></div><div style="font-size:11pt;"><a style="font-family:Arial;font-size:11pt;" href="#"><font style="font-family:Arial;font-size:11pt;">carla.burigatto@haemonetics.com</font></a></div></td></tr></table></div></div><div style="line-height:144%;padding-top:10px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;"><br></font></div><div style="line-height:144%;padding-top:10px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-weight:bold;">HAEMONETICS ANNOUNCES HEADQUARTERS RELOCATION TO BOSTON</font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Braintree, Mass., Dec. 19, 2018 </font><font style="font-family:Arial;font-size:11pt;">- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">,</font><font style="font-family:Arial;font-size:11pt;">&#32;announced today that the company will be relocating its global headquarters to downtown Boston from its current location in Braintree, Massachusetts. Haemonetics&#8217; new headquarters will occupy over 62,000 square feet at 125 Summer Street. </font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">&#8220;Haemonetics&#8217; move to Boston will position our teams to work in close proximity to the city&#8217;s world-class healthcare, technology and higher education communities and its thriving culture of innovation,&#8221; said Chris Simon, President and CEO of Haemonetics.&#160;&#8220;As a company driving accelerated growth, this move will provide a dynamic space to engage our employees as we advance our ways of working.&#8221;</font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">&#160;</font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The new Boston headquarters will enable Haemonetics to right-size its footprint by selling its 40-acre campus in Braintree and will provide a sustainable, contemporary workplace, including dedicated lab and research space, to support the company&#8217;s collaborative, performance-driven culture.&#160;The company&#8217;s corporate and commercial teams will sit side by side with its research and development organizations. The company has signed a multiyear lease through 2032 and expects to have employees located across four floors of the 495,000 square foot LEED and Energy Star certified office tower.  </font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The new office location offers convenient access to Interstate 93, the Massachusetts Turnpike, Logan International Airport, Downtown Crossing and South Station, the city&#8217;s main multimode transportation center. The move to the new location is expected to commence within the next year. With approximately 3,000 global employees, Haemonetics expects to move its more than 200 headquarters based positions to the new location. </font></div><div><br></div><div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">"We're excited to welcome Haemonetics to 125 Summer Street as we continue to create a destination for innovative companies. We look forward to continuing our partnership with them</font><font style="font-family:Arial;font-size:11pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:11pt;">to create an inspiring workspace for their employees,&#8221; said Matthew Polhemus, Senior Leasing Manager at Oxford Properties.</font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Cushman &amp; Wakefield brokered the lease for Haemonetics with Oxford Properties Group, owner and manager of 125 Summer Street, and will also represent Haemonetics in the sale of the current Braintree campus. </font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">About Haemonetics </font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.</font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">FORWARD LOOKING STATEMENTS</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements.&#160; Forward-looking statements in this press release may include, without limitation, statements regarding the expected benefits and timing of Haemonetics&#8217; headquarters relocation and the potential sale of its Braintree campus.&#160; Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon Haemonetics&#8217; current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, delays in and costs associated with development and occupancy of the Summer Street location, economic conditions in the Boston, MA metropolitan area, and other risk factors identified and described in more detail in Haemonetics&#8217; periodic reports and other filings with the Securities and Exchange Commission. Haemonetics does not undertake to update these forward-looking statements.</font></div><div style="line-height:180%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">###</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>haemo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 haemo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "& =H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /C;QY_R/'B+_L(W'_HUJPJ
MW?'G_(\>(O\ L(W'_HUJPJ_4J/\ #CZ(_*JW\27JPHHHK8Q"BBB@ KZL^"/_
M "2_1?\ MM_Z/DKY3KZL^"/_ "2_1?\ MM_Z/DKY[//]VC_B7Y,^BR/_ 'F7
M^%_FCYQHHHK^ S]&"BBB@ HHHH *^K_!?_(G:%_UX0?^BUKY0KZO\%_\B=H7
M_7A!_P"BUK]6\/\ _>J_^%?F8U-D?.5%%%?LYF%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!J^%/^1HT?\ Z_(?_0Q6;_P41_Y(KHO_ &,,'_I-
M<UI>%/\ D:-'_P"OR'_T,5F_\%$?^2*Z+_V,,'_I-<UE7_@2/LN#?^2@P?\
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M6\/_ />J_P#A7YF-39'SE1117[.9A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 :OA3_ )&C1_\ K\A_]#%9O_!1'_DBNB_]C#!_Z37-:7A3_D:-
M'_Z_(?\ T,5F_P#!1'_DBNB_]C#!_P"DUS65?^!(^RX-_P"2@P?^/]&?G?11
M17S)_;P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'VS_P $U_\
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MG_BG_P $MS_\17Z^T4?V?'^8/^(M8W_H%A][/R"_X4=\1_\ HG_BG_P2W/\
M\11_PH[XC_\ 1/\ Q3_X);G_ .(K]?:*/[/C_,'_ !%K&_\ 0+#[V?D%_P *
M.^(__1/_ !3_ ."6Y_\ B*/^%'?$?_HG_BG_ ,$MS_\ $5^OM%']GQ_F#_B+
M6-_Z!8?>SY!_X)^^!_$G@S_A/?\ A(/#^J:%]I^P>1_:5E);^;M^T[MN]1NQ
MN7..F1ZU]?445Z%*FJ4%!=#\ESW-IY[F-3,:D%%SMHMM(J/Z!1116QX(4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#$9[;LU^E7@'X?MX&AF$GB77_$<TRJ&EUN]\_:1W1< +G-?E?\#O^2U?#_\
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MGIZU]:7G[,OQ':/_ $3X]>(TD /$T#L">PR)QC]:^+OV7?\ DX#P/_V$%_\
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M_0'KQK_@H;\+_+N-$\>V<7RR :;J&T?Q#+0N?J-ZD_[*"O9?'?\ R>!\,?\
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MG_L18)^RY7&_M/>UUO?DM>^NUO(R/"WBS2?&NCQZIHMXM]82,56959>1U&&
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MUBM';9674*^9OVM/CGX:_P"%8^)_"&EW5QJ?B.Z/V!K:UM9&$)60>:7<KM
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
